MGO One Seven LLC Invests $421,000 in Quest Diagnostics Incorporated (NYSE:DGX)

MGO One Seven LLC acquired a new position in Quest Diagnostics Incorporated (NYSE:DGX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 2,793 shares of the medical research company's stock, valued at approximately $421,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC lifted its holdings in shares of Quest Diagnostics by 35.9% during the 3rd quarter. Barclays PLC now owns 298,922 shares of the medical research company's stock worth $46,407,000 after acquiring an additional 78,980 shares during the last quarter. Te Ahumairangi Investment Management Ltd raised its position in Quest Diagnostics by 3.1% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 50,004 shares of the medical research company's stock valued at $7,719,000 after purchasing an additional 1,520 shares in the last quarter. Pine Valley Investments Ltd Liability Co lifted its stake in Quest Diagnostics by 13.1% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 34,708 shares of the medical research company's stock worth $5,388,000 after purchasing an additional 4,024 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Quest Diagnostics during the third quarter worth about $201,000. Finally, Franklin Resources Inc. boosted its holdings in shares of Quest Diagnostics by 45.8% in the 3rd quarter. Franklin Resources Inc. now owns 54,897 shares of the medical research company's stock worth $8,180,000 after purchasing an additional 17,240 shares in the last quarter. Hedge funds and other institutional investors own 88.06% of the company's stock.

Quest Diagnostics Trading Down 0.5 %

DGX stock traded down $0.83 on Thursday, reaching $177.39. The company's stock had a trading volume of 857,292 shares, compared to its average volume of 961,867. The business has a fifty day simple moving average of $169.31 and a two-hundred day simple moving average of $161.59. Quest Diagnostics Incorporated has a 12-month low of $135.27 and a 12-month high of $179.37. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.02 and a current ratio of 1.10. The firm has a market cap of $19.80 billion, a PE ratio of 23.07, a PEG ratio of 2.16 and a beta of 0.78.

Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical research company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.06. Quest Diagnostics had a return on equity of 15.07% and a net margin of 8.80%. The company had revenue of $2.65 billion for the quarter, compared to analyst estimates of $2.63 billion. As a group, research analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current year.

Insider Buying and Selling at Quest Diagnostics

In related news, SVP Mark E. Delaney sold 403 shares of Quest Diagnostics stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $164.30, for a total value of $66,212.90. Following the completion of the sale, the senior vice president now directly owns 4,624 shares in the company, valued at approximately $759,723.20. This trade represents a 8.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO J. E. Davis sold 39,191 shares of the company's stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $168.46, for a total transaction of $6,602,115.86. Following the transaction, the chief executive officer now owns 127,623 shares in the company, valued at $21,499,370.58. This represents a 23.49 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 55,903 shares of company stock worth $9,460,221. 8.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on DGX. Leerink Partnrs upgraded Quest Diagnostics from a "hold" rating to a "strong-buy" rating in a research report on Monday, January 6th. Leerink Partners upgraded shares of Quest Diagnostics from a "market perform" rating to an "outperform" rating and boosted their price objective for the stock from $169.00 to $174.00 in a report on Monday, January 6th. Truist Financial increased their target price on shares of Quest Diagnostics from $182.00 to $190.00 and gave the company a "hold" rating in a report on Wednesday, April 23rd. Redburn Atlantic initiated coverage on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price target for the company. Finally, Citigroup cut Quest Diagnostics from a "buy" rating to a "neutral" rating and set a $185.00 price objective on the stock. in a research note on Tuesday, March 4th. Eight investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Quest Diagnostics has an average rating of "Moderate Buy" and an average price target of $185.07.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.